IceCure Reports Positive 5-Year Top-Line Results via 6-K Filing

TL;DR

**IceCure just dropped positive 5-year clinical data, big news for the stock!**

AI Summary

IceCure Medical Ltd. filed a 6-K on March 25, 2026, to report positive 5-year top-line results, as detailed in a press release dated the same day. This filing indicates the company is sharing significant clinical data, which could positively impact investor confidence and the stock price, as it suggests progress in their medical device development and potential market adoption.

Why It Matters

Positive clinical results can significantly de-risk a medical device company, potentially leading to increased sales, market share, and a higher stock valuation.

Risk Assessment

Risk Level: low — This filing reports positive news, which generally reduces investment risk by providing favorable clinical data.

Analyst Insight

A smart investor would review the full press release for details on the 5-year top-line results to understand the scope and implications of the positive data, potentially considering an investment or increasing their position if the details are compelling.

Key Players & Entities

• IceCure Medical Ltd. (company) — the filer of the 6-K
• March 25, 2026 (date) — the filing date and date of the press release
• 0001584371 (company) — IceCure Medical Ltd.'s CIK

Forward-Looking Statements

• IceCure Medical Ltd.'s stock price will see an increase due to the positive clinical results. (IceCure Medical Ltd.) — medium confidence, target: 2026-04-25
• Analyst ratings for IceCure Medical Ltd. will improve following the release of positive 5-year top-line data. (IceCure Medical Ltd.) — medium confidence, target: 2026-06-25

FAQ

Filing Documents

• ea0283312-6k_icecure.htm (6-K) — 12KB
• ea028331201ex99-1.htm (EX-99.1) — 16KB
• 0001213900-26-033860.txt ( ) — 28KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 7) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F CONTENTS On March 25, 2026, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K. This Report of Foreign Private Issuer on Form 6-K (excluding the fifth paragraph of the press release included as Exhibit 99.1 hereto) is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046 and 333-258660 ) and Form S-8 (File Nos. 333-270982 , 333-264578 , 333-262620 and 333-281587 ), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Press Release dated March 25, 2026 titled “IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates” 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: March 25, 2026 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR